Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to Learn

posted 18 hours

Mashup Score: 9

OncLive - Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have...

Next Steps in Small Cell Lung Cancer Feature Closer Eye on Immunotherapy, Lurbinectedin

posted 1 day

Mashup Score: 4

OncLive - Benjamin Drapkin, MD, PhD, discusses the road ahead in small cell lung cancer research, and the challenges that still need to be solved in...

Telehealth Is Here to Stay: Opportunities and Challenges for Cancer Care

posted 22 hours

Mashup Score: 2

OncLive - Oncology practices across the United States have rapidly increased telehealth use in 2020 to mitigate the risk of coronavirus disease 2019 (COVID-19) to patients...

TP53 Mutations Among Prognostic Factors Associated With Ibrutinib-Resistant CLL

posted 2 days

Mashup Score: 2

OncLive - Patients with chronic lymphocytic leukemia who are at an increased risk of failure on ibrutinib can be identified prior to treatment initiation using a...

FDA Approves FoundationOne CDx for Larotrectinib in NTRK+ Tumors

posted 1 day

Mashup Score: 1

OncLive - The FDA has approved the FoundationOne CDx comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions...

FDA Grants Ublituximab/Umbralisib Combo Fast Track Status in CLL

posted 1 day

Mashup Score: 1

OncLive - The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the...

  • #ICYMI: The #FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of adult patients with CLL. @US_FDA #leusm https://t.co/tNTsGEOBpY

Surgical Oncology Is More Than Just Surgery

posted 3 hours

Mashup Score: 1

OncLive - After 15 years as a surgeon, Jeffrey M. Farma, MD, says he’s still learning how to treat patients with cancer. As fellowship director of...

Prostate Cancer Enters a New Era of Precision Medicine

posted 23 hours

Mashup Score: 1

OncLive - Daniel P. Petrylak, MD, discusses the ever-changing prostate cancer armamentarium, as well as the role of biomarkers and new diagnostic methods in the...

FDA Grants Ublituximab/Umbralisib Combo Fast Track Status in CLL

posted 2 days

Mashup Score: 1

OncLive - The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the...

  • Positive topline results of ublituximab plus umbralisib were unveiled from the phase 3 UNITY-CLL trial, in which the doublet improved PFS compared with obinutuzumab plus chlorambucil in patients with previously untreated and relapsed/refractory CLL. #leusm https://t.co/7OYSROI6RI

MD Anderson and Taiho Pharmaceutical Collaborate to Develop Therapies for Brain Metastases

posted 13 hours

Mashup Score: 1

OncLive - The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical have formed a collaboration to do preclinical and early clinical research on potential...